Regeneron has reported the enrollment of the first patient in the phase 3 program of VEGF Trap-Eye, for the treatment of central retinal vein occlusion (CRVO).
Regeneron has received a $20 million milestone payment from Bayer, with dosing of the first patient in the CRVO program.
The phase 3 program in CRVO consists of two multinational, one-year clinical studies – COPERNICUS and GALILEO.
The primary endpoint of both the studies is improvement in visual acuity versus baseline after six months of treatment. At the end of the initial six months, patients will be dosed on a PRN basis for another six months. All patients will be eligible for rescue laser treatment.
Results from both the CRVO studies are expected in 2011.